Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates

Core Viewpoint - Stoke Therapeutics, Inc. is focused on RNA medicine to restore protein expression and is developing zorevunersen as a potential disease-modifying treatment for Dravet syndrome [1] Company Overview - Stoke Therapeutics is a biotechnology company dedicated to harnessing the body's potential through RNA medicine [1] - The company has a lead investigational medicine, zorevunersen, which is positioned as a first-in-class treatment for Dravet syndrome [1] Upcoming Events - Management will host a webcast and conference call for analysts and investors on November 4, 2025, at 4:30 p.m. E [1]